Moors & Cabot, Inc. Tcr2 Therapeutics Inc. Transaction History

Moors & Cabot, Inc.

  • $1.96 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 05, 2021
BUY
$8.44 - $18.35 $211,000 - $458,750
25,000 New
25,000 $25,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Moors & Cabot, Inc. Portfolio

Follow Moors & Cabot, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email